Chemotherapy for advanced pancreatic cancer

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Single-agent gemcitabine is the established standard for advanced pancreatic cancer, following superiority over 5-fluorouracil (FU).
• Recent trials of gemcitabine-based combinations have largely failed to demonstrate improved survival compared to gemcitabine alone.
• The emergence of novel targeted agents is also influencing treatment strategies.

Purpose of the Study:

• To review and discuss clinical trials in advanced pancreatic cancer chemotherapy.
• To evaluate the efficacy of gemcitabine-based combinations and novel targeted agents.
• To identify potential standard treatments for first-line and second-line therapy.

Main Methods:

• Review of randomized clinical trials comparing chemotherapy regimens for advanced pancreatic cancer.
• Analysis of studies evaluating gemcitabine monotherapy versus combination therapies.
• Examination of trials investigating novel targeted agents and second-line treatments.

Main Results:

• Gemcitabine demonstrated superior clinical benefit response compared to 5-fluorouracil (FU).
• Combination gemcitabine and capecitabine shows positive interim results, potentially becoming a new standard in the UK.
• Oxaliplatin with FU and leucovorin suggests superiority over best supportive care for gemcitabine-refractory patients.

Conclusions:

• Gemcitabine remains a cornerstone treatment for advanced pancreatic cancer.
• Combination therapy with gemcitabine and capecitabine is a promising development for first-line treatment.
• Oxaliplatin-based chemotherapy represents a potential option for second-line treatment in refractory cases.